367 related articles for article (PubMed ID: 37936692)
1. Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer.
Yu P; Wang Y; Yuan D; Sun Y; Qin S; Li T
Front Immunol; 2023; 14():1276694. PubMed ID: 37936692
[TBL] [Abstract][Full Text] [Related]
2. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.
Qian C; Liu C; Liu W; Zhou R; Zhao L
Front Immunol; 2023; 14():1291530. PubMed ID: 38193080
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
McGray AJR; Huang RY; Battaglia S; Eppolito C; Miliotto A; Stephenson KB; Lugade AA; Webster G; Lichty BD; Seshadri M; Kozbor D; Odunsi K
J Immunother Cancer; 2019 Jul; 7(1):189. PubMed ID: 31315674
[TBL] [Abstract][Full Text] [Related]
4. Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy.
Rajtak A; Ostrowska-Leśko M; Żak K; Tarkowski R; Kotarski J; Okła K
Front Immunol; 2022; 13():1018256. PubMed ID: 36439144
[TBL] [Abstract][Full Text] [Related]
5. Alleviating hypoxia to improve cancer immunotherapy.
Fan P; Zhang N; Candi E; Agostini M; Piacentini M; ; Shi Y; Huang Y; Melino G
Oncogene; 2023 Dec; 42(49):3591-3604. PubMed ID: 37884747
[TBL] [Abstract][Full Text] [Related]
6. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
7. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.
Abou Khouzam R; Brodaczewska K; Filipiak A; Zeinelabdin NA; Buart S; Szczylik C; Kieda C; Chouaib S
Front Immunol; 2020; 11():613114. PubMed ID: 33552076
[TBL] [Abstract][Full Text] [Related]
8. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
[TBL] [Abstract][Full Text] [Related]
9. Inducing vascular normalization: A promising strategy for immunotherapy.
Luo X; Zou W; Wei Z; Yu S; Zhao Y; Wu Y; Wang A; Lu Y
Int Immunopharmacol; 2022 Nov; 112():109167. PubMed ID: 36037653
[TBL] [Abstract][Full Text] [Related]
10. Normalization of the tumor microvasculature based on targeting and modulation of the tumor microenvironment.
Li Z; Ning F; Wang C; Yu H; Ma Q; Sun Y
Nanoscale; 2021 Oct; 13(41):17254-17271. PubMed ID: 34651623
[TBL] [Abstract][Full Text] [Related]
11. Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy.
Meo C; de Nigris F
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339244
[TBL] [Abstract][Full Text] [Related]
12. Immune Therapy Opportunities in Ovarian Cancer.
Kandalaft LE; Odunsi K; Coukos G
Am Soc Clin Oncol Educ Book; 2020 May; 40():1-13. PubMed ID: 32412818
[TBL] [Abstract][Full Text] [Related]
13. Immunity and immune suppression in human ovarian cancer.
Preston CC; Goode EL; Hartmann LC; Kalli KR; Knutson KL
Immunotherapy; 2011 Apr; 3(4):539-56. PubMed ID: 21463194
[TBL] [Abstract][Full Text] [Related]
14. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
15. Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer.
Buka D; Dvořák J; Richter I; Škrobánek P; Buchler T; Melichar B
Acta Medica (Hradec Kralove); 2019; 62(3):127-130. PubMed ID: 31431233
[TBL] [Abstract][Full Text] [Related]
16. Targeted immune therapy of ovarian cancer.
Knutson KL; Karyampudi L; Lamichhane P; Preston C
Cancer Metastasis Rev; 2015 Mar; 34(1):53-74. PubMed ID: 25544369
[TBL] [Abstract][Full Text] [Related]
17. Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment.
Melo V; Bremer E; Martin JD
Front Cell Dev Biol; 2022; 10():908389. PubMed ID: 35712656
[TBL] [Abstract][Full Text] [Related]
18. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
19. Combining microenvironment normalization strategies to improve cancer immunotherapy.
Mpekris F; Voutouri C; Baish JW; Duda DG; Munn LL; Stylianopoulos T; Jain RK
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3728-3737. PubMed ID: 32015113
[TBL] [Abstract][Full Text] [Related]
20. The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors.
Baci D; Bosi A; Gallazzi M; Rizzi M; Noonan DM; Poggi A; Bruno A; Mortara L
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32354198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]